Lantheus Holdings just printed Q1 2026. The numbers confirm a transition-year trough; the call disclosed something that doesn't show up in the 10-Q. The stock is fairly priced to a probability-weighted target. The trade isn't on the stock — it's on the tail asymmetry.

What the filing says

PYLARIFY (61% of revenue) printed $240.9M, -6.5% YoY — the identical decline rate as FY2025. The CFO said it plainly: "almost delivering exactly the same number for each of the last 3 quarters in a row." Quarterly run-rate is locked at $240-243M. Volume +5.8%, price compressing, rebate reserve still building ($66.4M → $69.9M).

The CCO disclosed something the market didn't have: TruVu — the new PYLARIFY formulation FDA-approved March 6, 2026 — has NOT yet had a TPT application filed. Only the HCPCS code application is in. HCPCS review takes ≈90 days, then TPT applies, then CMS reviews 9-15 months. Earliest plausible TPT grant: Q3-Q4 2027. The pricing reset is not a 2026 event.

Total revenue +1.2% YoY — entirely the Neuraceq acquisition contribution. Operating income -20.3%. Zero buybacks against $498.6M cash. CCO said the PSMA PET market is growing "low teens." PYLARIFY volume +5.8% means LNTH is growing at half the market rate.

What the market thinks

Forward P/E 11.59. Calls IV trades 3.9% above puts (bullish positioning into a trough). RSI 68.7, +14.3% 1M, 10.4% short interest.

Probability-weighted scenario target ($65 deep-bear / $90 sideways / $107 pipeline-lifts / $140 squeeze) = $93.40. Spot is fair to PWAT. Directional bets have ~zero EV before borrow.

The skew tells a different story. Implied probabilities back out as: deep-bear ≈10%, sideways ≈50%, pipeline ≈25%, squeeze ≈15%. Our reading: deep-bear ≈20%, sideways ≈50%, pipeline ≈20%, squeeze ≈10%. Market is over-paying for the right tail (≈5pp) and under-paying for the left (≈10pp).

Why the gap exists

Cross-vertical coverage. NVS Q1 2026 disclosed Pluvicto NBRX +48% and US sites 730 → 830+ (+14% in two quarters) — every Pluvicto patient requires a PSMA-positive scan to qualify. The math forces PSMA imaging volume +20%+, not "low teens." If PYLARIFY is +5.8%, share is moving to the bundled diagnostic (Locametz). Pure-play diagnostics lose share inside paired-therapy expansion. NVS analysts cover oncology; LNTH analysts cover radiopharma. Neither synthesizes the other.

CAH Q3 FY2026 confirmed the structural piece: Theranostics sub-segment +30% YoY versus LNTH PYLARIFY -6.5%. The 36-percentage-point gap isn't sectoral plateau — it's distribution moat. TLX received a fresh 3-year TPT for Gozellix in 6 months FDA-approval-to-grant. CMS posture isn't tightening — the LNTH delay is execution lag.

Risks

1. MK-6240 Pharma Solutions revenue is the bear-thesis killer. Strategic Partnerships printed $16.3M (+52% YoY) with MK-6240 over half — ≈$32-36M annualized from 17 pharma trial contracts BEFORE commercial approval. If sell-side currently models MK-6240 as a 2027+ commercial story, this revenue layer is invisible. Q2/Q3 prints could trigger upward EPS revisions.
2. New CEO appointment with strong commercial track record drives sentiment re-rating regardless of fundamentals.
3. MK-6240 strong approval label (P=72%).
4. Radiopharma M&A premium — sector consolidation continues.

Catalysts

What would change our mind

• MK-6240 + Pharma Solutions Q3 revenue ≥$20M → bear thesis loses ≈30% of edge.
• PYLARIFY Q2 above $250M → idio compression thesis breaks; structural framing was wrong.
• TruVu TPT application filed early Q3 with expedited review mechanism → conditional bull reactivates.
• Three or more radiopharma peers cite the same paired-therapy diagnostic dynamic in Q2 prints → reframes as sectoral, not LNTH-idio.

Evidence